Latest Breaking News On - Taiwan national cheng kung university in tainan - Page 1 : comparemela.com

Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.

United statesRoys herbstAmerican society of clinical oncologyYale school of medicineYale cancer centerJapan the national cancer center hospitalKanagawa cancer centerTaiwan national cheng kung university in tainanYale schoolAmerican societyClinical oncologyNational cancer center hospital eastNational cheng kung university